DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 16350.0
(-1.57%)
KRW 16350.0
(-1.57%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 839.53 Billion KRW | 9.27% |
| 2022 | 768.33 Billion KRW | 2.43% |
| 2021 | 750.07 Billion KRW | 11.19% |
| 2020 | 674.58 Billion KRW | 23.92% |
| 2019 | 544.38 Billion KRW | 13.36% |
| 2018 | 480.24 Billion KRW | 25.99% |
| 2017 | 381.16 Billion KRW | 14.93% |
| 2016 | 331.65 Billion KRW | 18.04% |
| 2015 | 280.96 Billion KRW | 15.07% |
| 2014 | 244.16 Billion KRW | 11.87% |
| 2013 | 218.25 Billion KRW | 13.59% |
| 2012 | 192.14 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 901.39 Billion KRW | 4.04% |
| 2024 Q1 | 866.38 Billion KRW | 3.2% |
| 2023 Q3 | 824.9 Billion KRW | 2.48% |
| 2023 Q4 | 839.53 Billion KRW | 1.77% |
| 2023 FY | 839.53 Billion KRW | 9.27% |
| 2023 Q1 | 792.3 Billion KRW | 3.12% |
| 2023 Q2 | 804.93 Billion KRW | 1.59% |
| 2022 Q1 | 747.58 Billion KRW | -0.33% |
| 2022 Q3 | 760.63 Billion KRW | 2.66% |
| 2022 Q2 | 740.91 Billion KRW | -0.89% |
| 2022 FY | 768.33 Billion KRW | 2.43% |
| 2022 Q4 | 768.33 Billion KRW | 1.01% |
| 2021 Q4 | 750.07 Billion KRW | 4.81% |
| 2021 Q1 | 684.93 Billion KRW | 3.28% |
| 2021 FY | 750.07 Billion KRW | 11.19% |
| 2021 Q2 | 717.18 Billion KRW | 4.71% |
| 2021 Q3 | 715.65 Billion KRW | -0.21% |
| 2020 Q4 | 663.16 Billion KRW | 1.44% |
| 2020 Q3 | 653.72 Billion KRW | 4.88% |
| 2020 FY | 674.58 Billion KRW | 23.92% |
| 2020 Q1 | 572.19 Billion KRW | 5.11% |
| 2020 Q2 | 623.33 Billion KRW | 8.94% |
| 2019 Q4 | 544.38 Billion KRW | 0.74% |
| 2019 Q1 | 507.67 Billion KRW | 5.71% |
| 2019 Q2 | 518.51 Billion KRW | 2.14% |
| 2019 Q3 | 540.4 Billion KRW | 4.22% |
| 2019 FY | 544.38 Billion KRW | 13.36% |
| 2018 Q2 | 408.68 Billion KRW | 4.58% |
| 2018 FY | 480.24 Billion KRW | 25.99% |
| 2018 Q4 | 480.24 Billion KRW | 10.51% |
| 2018 Q3 | 434.56 Billion KRW | 6.33% |
| 2018 Q1 | 390.8 Billion KRW | 4.69% |
| 2017 Q4 | 373.3 Billion KRW | 1.86% |
| 2017 FY | 381.16 Billion KRW | 14.93% |
| 2017 Q1 | 327.15 Billion KRW | 0.63% |
| 2017 Q2 | 339.29 Billion KRW | 3.71% |
| 2017 Q3 | 366.5 Billion KRW | 8.02% |
| 2016 Q2 | 297.51 Billion KRW | 4.23% |
| 2016 FY | 331.65 Billion KRW | 18.04% |
| 2016 Q1 | 285.43 Billion KRW | 3.87% |
| 2016 Q3 | 309.71 Billion KRW | 4.1% |
| 2016 Q4 | 325.09 Billion KRW | 4.97% |
| 2015 Q2 | 258.75 Billion KRW | 4.45% |
| 2015 FY | 280.96 Billion KRW | 15.07% |
| 2015 Q3 | 266.43 Billion KRW | 2.97% |
| 2015 Q1 | 247.73 Billion KRW | 1.46% |
| 2015 Q4 | 274.79 Billion KRW | 3.14% |
| 2014 FY | 244.16 Billion KRW | 11.87% |
| 2014 Q1 | 222.63 Billion KRW | 2.01% |
| 2014 Q3 | 239.23 Billion KRW | 5.24% |
| 2014 Q2 | 227.32 Billion KRW | 2.1% |
| 2014 Q4 | 244.16 Billion KRW | 2.06% |
| 2013 Q3 | 217.2 Billion KRW | 5.54% |
| 2013 FY | 218.25 Billion KRW | 13.59% |
| 2013 Q2 | 205.79 Billion KRW | 3.98% |
| 2013 Q4 | 218.25 Billion KRW | 0.49% |
| 2013 Q1 | 197.9 Billion KRW | 3.0% |
| 2012 FY | 192.14 Billion KRW | 0.0% |
| 2012 Q3 | 190.02 Billion KRW | 0.0% |
| 2012 Q4 | 192.14 Billion KRW | 1.12% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 141.35 Billion KRW | -493.934% |
| CMG Pharmaceutical Co., Ltd. | 186.85 Billion KRW | -349.305% |
| Celltrion Pharm, Inc. | 641.64 Billion KRW | -30.841% |
| Huons Global Co., Ltd. | 1317.96 Billion KRW | 36.301% |
| Enzychem Lifesciences Corporation | 211.54 Billion KRW | -296.858% |
| Humedix Co., Ltd. | 219.97 Billion KRW | -281.646% |
| Boditech Med Inc. | 227.9 Billion KRW | -268.376% |
| EuBiologics Co., Ltd. | 172.64 Billion KRW | -386.287% |
| FutureChem Co.,Ltd | 72.83 Billion KRW | -1052.682% |
| Huons Co., Ltd. | 537.28 Billion KRW | -56.255% |
| BNC Korea Co., Ltd. | 236.15 Billion KRW | -255.506% |
| AptaBio Therapeutics Inc. | 92.51 Billion KRW | -807.418% |